Adjuvant and neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma

• 作者: Büchler Markus W. Hackert Thilo Klaiber Ulla Leonhardt Carl S. Neoptolemos John P. Strobel Oliver Traub Benno
• 来源期刊: 胰腺病学杂志（英文）
• 关键词: Adjuvant therapy ESPAC Neoadjuvant therapy Pancreatectomy Pancreatic cancer Randomized trial
• 年，卷（期）: 2020,（1）
• 所属期刊栏目: Review Article
• 页码范围: 1-11
• 页数: 11页
• 语种: 中文
• DOI: 10.1097/JP9.0000000000000040

摘要

The management of pancreatic cancer has dramatically changed since the first major randomized trial published in 2001 by the European Study Group for Pancreatic Cancer (ESPAC) stimulated the development of multimodality oncosurgical therapies. ESPAC-1 demonstrated a survival improvement from upfront surgery of only 8%, increasing to 21% 5-year survival for 5-fluorouracil/folinic acid but only 10.8% for chemoradiotherapy. ESPAC-4 has shown a 5-year survival rate of 30% for all patients without restriction of 30% using a combination of gemcitabine and capecitabine, rising to 40% in those with an R0 resection margin, or nearly 50% in those with N0 lymph node status. In selected patients with favorable prognostic features mFOLFIRINOX can produce a 50% 5-year survival rate but with added toxicity. While a positive resection margin is associated with an increased likelihood of local recurrence, this of itself is not the contributor to reduced survival, but rather reflects the increased probability of systemic disease. Thus, strategies aimed at local control, may reduce subsequent local progression, but will not improve overall survival. Neoadjuvant chemotherapy is increasingly utilized in cases of borderline resectable or locally advanced pancreatic cancer, but there is still a lack of proof of concept studies. High-quality evidence from randomized controlled trials to identify the indications and benefits of neoadjuvant therapy in pancreatic cancer are required. The use of patient-derived tumor organoids may predict response to chemotherapy which could open a new opportunity in pancreatic cancer treatment, stratifying patients into treatment groups based on their response to these therapies in the laboratory.